The strong efficacy data in frontline AML supports ziftomenib's potential label expansion, which could significantly increase peak sales. Monitor EHA 2026 presentation on June 14 for updated durability and safety data, and the virtual investor call on June 3 for additional context. The Phase 3 KOMET-017 enrollment progress will be a key catalyst.
Price Chart
Executive Summary
Kura Oncology announced that updated Phase 1 KOMET-007 data for ziftomenib in frontline AML will be presented at EHA 2026. The 99-patient dataset shows high CRc rates (90-96%) and deep MRD negativity (>80%) across NPM1-m and KMT2A-r subtypes, with median duration of CRc not reached in NPM1-m patients at ~15 months follow-up. The Phase 3 KOMET-017 trial is enrolling, with potential for accelerated FDA review in 2028.
Key Facts
- Oral presentation at EHA 2026 on June 14 will feature 99-patient dataset with extended follow-up
- CRc rates: 96% (NPM1-m) and 90% (KMT2A-r) in frontline AML
- MRD-negativity rates: 83% (NPM1-m) and 82% (KMT2A-r) among CRc responders
- Median duration of CRc not reached in NPM1-m at 14.9 months median follow-up
- Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028
- Ziftomenib already FDA-approved as KOMZIFTI for R/R NPM1-m AML
Financial Impact
No financial figures disclosed; potential to expand ziftomenib's addressable market from R/R to frontline AML, which represents a larger patient population
Risk Factors
- Differentiation syndrome remains a boxed warning risk (26% incidence in R/R AML)
- Phase 3 KOMET-017 trial may fail to replicate Phase 1 results
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Potential for accelerated FDA review in 2028 is aspirational and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293020 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access